LEGN (Legend Biotech) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEGN Legend Biotech Corp LEGN
74 GF Score
Price $20.27
GF Value $79.10
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Legend Biotech Short-term investments?

Short-term investments only applies to insurance companies.

LEGN
74GF Score
Legend Biotech Corp LEGN
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Legend Biotech (LEGN) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of $20.27 is trading 74.4% below its estimated GF Value™ of $79.10. GuruFocus considers Legend Biotech to be Significantly Undervalued.

Key valuation signals for LEGN:

  • Short-term investments:
  • GF Value™: $79.10 vs. price of $20.27 (74.4% below fair value)
  • GF Score™: 74/100 with 2 warning signs

No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Legend Biotech Business Description

Other Exchanges 9LB:Germany
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
74GF Score

Get the complete analysis for LEGN

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.27
Price
$79.10
GF Value